Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Equities research analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Foghorn Therapeutics in a note issued to investors on Thursday, March 13th. B. Riley analyst K. Patel forecasts that the company will post earnings per share of ($0.34) for the quarter. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for Foghorn Therapeutics' current full-year earnings is ($1.55) per share. B. Riley also issued estimates for Foghorn Therapeutics' Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.09) EPS and FY2027 earnings at ($1.34) EPS.
Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.13. The firm had revenue of $2.86 million for the quarter, compared to the consensus estimate of $8.56 million.
A number of other equities research analysts have also recently issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $13.00 target price on shares of Foghorn Therapeutics in a research note on Friday, March 7th. Jefferies Financial Group cut their target price on Foghorn Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a research note on Monday, December 16th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $13.17.
Get Our Latest Analysis on FHTX
Foghorn Therapeutics Stock Down 5.7 %
FHTX stock traded down $0.26 during mid-day trading on Monday, reaching $4.19. The company had a trading volume of 82,233 shares, compared to its average volume of 129,352. The stock has a market capitalization of $232.74 million, a P/E ratio of -2.17 and a beta of 3.13. Foghorn Therapeutics has a one year low of $3.86 and a one year high of $10.25. The stock's 50-day simple moving average is $4.68 and its two-hundred day simple moving average is $6.52.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of FHTX. Raymond James Financial Inc. acquired a new position in shares of Foghorn Therapeutics during the fourth quarter valued at $9,579,000. Point72 Asset Management L.P. raised its position in Foghorn Therapeutics by 58.8% in the fourth quarter. Point72 Asset Management L.P. now owns 634,761 shares of the company's stock worth $2,996,000 after acquiring an additional 235,059 shares in the last quarter. Deerfield Management Company L.P. Series C raised its position in Foghorn Therapeutics by 7.5% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 3,255,514 shares of the company's stock worth $15,366,000 after acquiring an additional 227,628 shares in the last quarter. DAFNA Capital Management LLC raised its position in Foghorn Therapeutics by 395.7% in the fourth quarter. DAFNA Capital Management LLC now owns 186,717 shares of the company's stock worth $881,000 after acquiring an additional 149,053 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Foghorn Therapeutics by 27.5% in the third quarter. Geode Capital Management LLC now owns 677,386 shares of the company's stock worth $6,308,000 after acquiring an additional 146,276 shares in the last quarter. 61.55% of the stock is owned by institutional investors and hedge funds.
About Foghorn Therapeutics
(
Get Free Report)
Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
See Also
Before you consider Foghorn Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Foghorn Therapeutics wasn't on the list.
While Foghorn Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
